Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc. has a partnership with Invitae Corporation to offer epilepsy panel testing. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was founded in 2014 and is headquartered in Bedford, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone781-430-8200
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees44
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable
Stoke Therapeutics (NASDAQ:STOK) Frequently Asked Questions
What is Stoke Therapeutics' stock symbol?
Stoke Therapeutics trades on the NASDAQ under the ticker symbol "STOK."
How were Stoke Therapeutics' earnings last quarter?
Stoke Therapeutics (NASDAQ:STOK) announced its quarterly earnings results on Wednesday, August, 14th. The company reported ($1.54) EPS for the quarter, missing analysts' consensus estimates of ($0.96) by $0.58. View Stoke Therapeutics' Earnings History.
When is Stoke Therapeutics' next earnings date?
What price target have analysts set for STOK?
4 brokerages have issued twelve-month price targets for Stoke Therapeutics' shares. Their predictions range from $34.00 to $44.00. On average, they anticipate Stoke Therapeutics' stock price to reach $37.67 in the next year. This suggests a possible upside of 80.7% from the stock's current price. View Analyst Price Targets for Stoke Therapeutics.
What is the consensus analysts' recommendation for Stoke Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stoke Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Stoke Therapeutics.
Has Stoke Therapeutics been receiving favorable news coverage?
News articles about STOK stock have trended negative this week, InfoTrie reports. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Stoke Therapeutics earned a coverage optimism score of -2.8 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Stoke Therapeutics.
Are investors shorting Stoke Therapeutics?
Stoke Therapeutics saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 635,900 shares, an increase of 78.2% from the August 30th total of 356,800 shares. Based on an average trading volume of 188,200 shares, the days-to-cover ratio is presently 3.4 days. Currently, 4.1% of the company's shares are short sold. View Stoke Therapeutics' Current Options Chain.
Who are some of Stoke Therapeutics' key competitors?
Some companies that are related to Stoke Therapeutics include Emergent Biosolutions (EBS), Genmab A/S (GMAB), Myokardia (MYOK), Ultragenyx Pharmaceutical (RARE), Arena Pharmaceuticals (ARNA), HUTCHISON CHINA/S (HCM), Biohaven Pharmaceutical (BHVN), PTC Therapeutics (PTCT), BridgeBio Pharma (BBIO), Ra Pharmaceuticals (RARX), Cambrex (CBM), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), Intercept Pharmaceuticals (ICPT) and Xencor (XNCR).
What other stocks do shareholders of Stoke Therapeutics own?
Who are Stoke Therapeutics' key executives?
Stoke Therapeutics' management team includes the folowing people:
- Dr. Edward M. Kaye, CEO & Director (Age 70)
- Dr. Adrian R. Krainer, Co-Founder & Director (Age 60)
- Ms. Isabel Aznarez, Co-Founder, VP & Head of Biology
- Mr. Stephen J. Tulipano CPA, MBA, Chief Financial Officer (Age 60)
- Dr. Huw M. Nash Ph.D., COO & Chief Bus. Officer (Age 52)
When did Stoke Therapeutics IPO?
(STOK) raised $100 million in an IPO on Wednesday, June 19th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity was co-manager.
When does the company's lock-up period expire?
Stoke Therapeutics' lock-up period expires on Monday, December 16th. Stoke Therapeutics had issued 7,891,110 shares in its public offering on June 19th. The total size of the offering was $142,039,980 based on an initial share price of $18.00. After the expiration of the company's lock-up period, major shareholders and company insiders will be able to sell their shares of the company.
How do I buy shares of Stoke Therapeutics?
Shares of STOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Stoke Therapeutics' stock price today?
One share of STOK stock can currently be purchased for approximately $20.84.
How big of a company is Stoke Therapeutics?
What is Stoke Therapeutics' official website?
How can I contact Stoke Therapeutics?
Stoke Therapeutics' mailing address is 45 WIGGINS AVENUE, BEDFORD MA, 01730. The company can be reached via phone at 781-430-8200 or via email at [email protected]
MarketBeat Community Rating for Stoke Therapeutics (NASDAQ STOK)
MarketBeat's community ratings are surveys of what our community members think about Stoke Therapeutics and other stocks. Vote "Outperform" if you believe STOK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STOK will underperform the S&P 500 over the long term. You may vote once every thirty days.
